Tourmaline Strengthens Cardiovascular Scientific Advisory Board with Appointment of Dr. Paul M. Ridker
Tourmaline Bio (NASDAQ: TRML) has appointed Dr. Paul M. Ridker to its Cardiovascular Scientific Advisory Board. Dr. Ridker, who serves as Eugene Braunwald Professor of Medicine at Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital, brings over 30 years of expertise in cardiovascular disease research.
Dr. Ridker's contributions include developing the first FDA-approved diagnostic test for vascular inflammation (hs-CRP), demonstrating statin therapy's dual lipid-lowering and anti-inflammatory effects, and proving the inflammation hypothesis of atherothrombosis in humans. His work has led to the development of various anti-inflammatory agents targeting heart disease.
This appointment comes as Tourmaline awaits results from its Phase 2 TRANQUILITY trial and prepares for the future development of pacibekitug to reduce inflammation in cardiovascular diseases.
Tourmaline Bio (NASDAQ: TRML) ha nominato il Dott. Paul M. Ridker nel suo Comitato Consultivo Scientifico Cardiovascolare. Il Dott. Ridker, che ricopre il ruolo di Professore di Medicina Eugene Braunwald presso la Harvard Medical School e Direttore del Center for Cardiovascular Disease Prevention al Brigham and Women's Hospital, porta con sé oltre 30 anni di esperienza nella ricerca sulle malattie cardiovascolari.
Le contribuizioni del Dott. Ridker includono lo sviluppo del primo test diagnostico approvato dalla FDA per l'infiammazione vascolare (hs-CRP), la dimostrazione degli effetti duali della terapia con statine nel ridurre i lipidi e nel combattere l'infiammazione, e la prova dell'ipotesi infiammatoria dell'aterotrombosi negli esseri umani. Il suo lavoro ha portato allo sviluppo di vari agenti anti-infiammatori mirati alle malattie cardiache.
Questa nomina arriva mentre Tourmaline attende i risultati del suo studio di Fase 2 TRANQUILITY e si prepara per il futuro sviluppo di pacibekitug per ridurre l'infiammazione nelle malattie cardiovascolari.
Tourmaline Bio (NASDAQ: TRML) ha nombrado al Dr. Paul M. Ridker en su Consejo Asesor Científico Cardiovascular. El Dr. Ridker, que ocupa el cargo de Profesor de Medicina Eugene Braunwald en la Harvard Medical School y Director del Centro para la Prevención de Enfermedades Cardiovasculares en el Brigham and Women's Hospital, aporta más de 30 años de experiencia en la investigación de enfermedades cardiovasculares.
Las contribuciones del Dr. Ridker incluyen el desarrollo de la primera prueba diagnóstica aprobada por la FDA para la inflamación vascular (hs-CRP), la demostración de los efectos duales de la terapia con estatinas para reducir lípidos y combatir la inflamación, y la validación de la hipótesis de inflamación de la aterotrombosis en humanos. Su trabajo ha llevado al desarrollo de varios agentes antiinflamatorios dirigidos a enfermedades cardíacas.
Este nombramiento llega mientras Tourmaline espera los resultados de su ensayo de fase 2 TRANQUILITY y se prepara para el futuro desarrollo de pacibekitug para reducir la inflamación en enfermedades cardiovasculares.
투르말린 바이오 (NASDAQ: TRML)는 심혈관 과학 자문 위원회에 Dr. Paul M. Ridker를 임명했습니다. Dr. Ridker는 하버드 의대에서 유진 브라운월드 교수로 재직 중이며 브리검 여성 병원 심혈관 질환 예방 센터의 소장을 맡고 있으며, 심혈관 질환 연구에서 30년 이상의 경력을 보유하고 있습니다.
Dr. Ridker의 기여에는 혈관 염증에 대한 최초의 FDA 승인 진단 테스트(hs-CRP)의 개발, 스타틴 치료의 이중한 지질 저하 및 항염증 효과의 입증, 인간에서의 죽상혈전증에 대한 염증 가설 증명이 포함됩니다. 그의 연구는 심장 질환을 겨냥한 다양한 항염증제의 개발로 이어졌습니다.
이번 임명은 투르말린이 2상 TRANQUILITY 시험의 결과를 기다리고 있으며 심혈관 질환의 염증을 줄이기 위한 pacibekitug의 향후 개발을 준비하고 있는 상황에서 이루어졌습니다.
Tourmaline Bio (NASDAQ: TRML) a nommé le Dr Paul M. Ridker au sein de son Conseil Consultatif Scientifique Cardiovasculaire. Le Dr Ridker, qui est professeur de médecine Eugene Braunwald à la Harvard Medical School et directeur du Centre de prévention des maladies cardiovasculaires au Brigham and Women's Hospital, possède plus de 30 ans d'expertise dans la recherche sur les maladies cardiovasculaires.
Les contributions du Dr Ridker incluent le développement du premier test diagnostique approuvé par la FDA pour l'inflammation vasculaire (hs-CRP), la démonstration des effets double de la thérapie par statines pour abaisser les lipides et lutter contre l'inflammation, ainsi que la validation de l'hypothèse inflammatoire de l'athérotrombothie chez l'homme. Son travail a conduit au développement de divers agents anti-inflammatoires ciblant les maladies cardiaques.
Cette nomination survient alors que Tourmaline attend les résultats de son essai de phase 2 TRANQUILITY et se prépare pour le développement futur de pacibekitug pour réduire l'inflammation dans les maladies cardiovasculaires.
Tourmaline Bio (NASDAQ: TRML) hat Dr. Paul M. Ridker in seinen Wissenschaftlichen Beirat für kardiovaskuläre Erkrankungen berufen. Dr. Ridker ist Eugene Braunwald Professor für Medizin an der Harvard Medical School und Direktor des Zentrums für Prävention von kardiovaskulären Erkrankungen am Brigham and Women's Hospital und bringt über 30 Jahre Erfahrung in der Forschung zu kardiovaskulären Erkrankungen mit.
Zu den Beiträgen von Dr. Ridker gehören die Entwicklung des ersten von der FDA zugelassenen diagnostischen Tests für vaskuläre Entzündungen (hs-CRP), der Nachweis der doppelten Wirkung der Statintherapie zur Senkung der Lipide und zur Bekämpfung von Entzündungen sowie der Beweis der Entzündungshypothese der Atherothrombose beim Menschen. Seine Arbeit hat zur Entwicklung verschiedener entzündungshemmender Mittel geführt, die auf Herzerkrankungen abzielen.
Diese Ernennung erfolgt, während Tourmaline die Ergebnisse ihrer Phase-2-Studie TRANQUILITY erwartet und sich auf die zukünftige Entwicklung von pacibekitug zur Reduzierung von Entzündungen bei kardiovaskulären Erkrankungen vorbereitet.
- Strategic addition of a distinguished cardiovascular disease expert to the Scientific Advisory Board
- Timing aligns with ongoing Phase 2 TRANQUILITY trial results
- Strengthens expertise in inflammation-related cardiovascular treatments
- None.
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Paul M. Ridker, MD, MPH, Eugene Braunwald Professor of Medicine at the Harvard Medical School and Director of the Center for Cardiovascular Disease Prevention at Brigham and Women’s Hospital, has joined Tourmaline’s Cardiovascular Scientific Advisory Board (CV SAB).
“We are beyond honored to welcome Dr. Ridker, a luminary in the field who has helped to fundamentally transform our understanding of cardiovascular disease,” said Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer of Tourmaline. “Dr. Ridker’s many contributions to cardiovascular disease research cannot be overstated. His work over decades has illuminated the critical role of inflammation in atherosclerosis, as well as the potential therapeutic benefit of directly addressing inflammation to reduce the risk of major adverse cardiovascular events. We are thrilled to have his invaluable strategic guidance as we await the results from our Phase 2 TRANQUILITY trial and prepare for the expected future development of pacibekitug to reduce inflammation in cardiovascular diseases.”
Over a 30-year period, Dr. Ridker has led a paradigm shift in the understanding of atherosclerotic cardiovascular disease (ASCVD), highlighting the critical importance of inflammation, and in doing so, has impacted international guidelines for the diagnosis, treatment, and prevention of ASCVD. He and his collaborators provided the first FDA-approved diagnostic test for vascular inflammation (high-sensitivity C-reactive protein, or hs-CRP); the first demonstration that statin therapy is both lipid-lowering and anti-inflammatory; and the first proof-of-principle for the inflammation hypothesis of atherothrombosis in humans, in addition to bringing into clinical practice worldwide the concept of “residual inflammatory risk.” As a direct result of his work, multiple novel anti-inflammatory agents targeting interrelated aspects of heart disease ranging from chronic ASCVD to acute myocardial ischemia to heart failure are under development worldwide.
Dr. Ridker, a Distinguished Scientist of the American Heart Association and an elected member of the National Academy of Medicine, is known for his leadership of over 15 major, multi-national, randomized clinical trials. He has received continuous funding from the National Institutes of Health and is the recipient of multiple honorary degrees and international awards.
“Dr. Ridker is a world-renowned pioneer in inflammation and cardiovascular disease whose ground-breaking work bridges population science, translational research, and clinical trials,” said Emil deGoma, MD, Senior Vice President of Medical Research at Tourmaline. “We are grateful to have his expert guidance as we advance development of pacibekitug for the treatment of patients with cardiovascular disease driven by residual inflammatory risk. Research he has led for decades, including prospective cohort studies of hs-CRP and the landmark CANTOS IL-1β inhibition trial, provides foundational evidence to support the therapeutic potential of IL-6 inhibition, which is currently being tested in multiple cardiovascular outcome trials.”
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006). For more information about Tourmaline and pacibekitug, please visit https://www.tourmalinebio.com or follow us on LinkedIn or X.
About Pacibekitug
Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is currently developing pacibekitug in atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED) as its first two indications, with plans to expand into abdominal aortic aneurysm (AAA) and additional diseases in the future.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe,” “designed to,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Tourmaline’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of pacibekitug; the timing of initiation, progress and results of Tourmaline’s current and future clinical trials for pacibekitug, including reporting of data therefrom; the timing of Phase 3 clinical trial readiness; and the timing and potential to expand pacibekitug into additional indications. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Tourmaline’s current or future product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Tourmaline’s current or future product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Tourmaline’s current or future product candidates; the risk that Tourmaline’s current or future product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Tourmaline anticipates; risks regarding the accuracy of Tourmaline’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts of macroeconomic conditions Tourmaline’s business, clinical trials and financial position; and other risks and uncertainties that are described in Tourmaline’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on November 7 2024 and other filings that Tourmaline makes with the SEC from time to time. Any forward-looking statements speak only as of the date of this press release and are based on information available to Tourmaline as of the date hereof, and Tourmaline assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
FAQ
What is the significance of Dr. Ridker joining TRML's Scientific Advisory Board?
What are the key achievements of Dr. Ridker that benefit TRML?
How does Dr. Ridker's appointment relate to TRML's TRANQUILITY trial?
What is the current status of TRML's TRANQUILITY trial in 2025?
